Clinical Trials Using Galunisertib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Galunisertib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Enzalutamide with or without Galunisertib in Treating Patients with Metastatic Castrate Resistant Prostate Cancer
This randomized phase II trial studies how well giving enzalutamide with or without galunisertib works in treating patients with prostate cancer that has spread to other places in the body (metastatic) and keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant). Enzalutamide may help slow or stop the growth of prostate cancer cells by blocking testosterone production in the body. Some tumors need growth factors, which are made by the body's white blood cells, to keep growing. Galunisertib may interfere with growth factors and help cause tumor cells to die. It is not yet known whether enzalutamide works better alone or with galunisertib in treating patients with castrate resistant prostate cancer.
Location: 6 locations
Paclitaxel, Carboplatin, and Galunisertib in Treating Patients with Newly Diagnosed, Persistent, or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Carcinosarcoma
This phase Ib trial studies the side effects and how well paclitaxel, carboplatin, and galunisertib work in treating patients with uterine, ovarian, fallopian tube, or peritoneal carcinosarcoma that is newly diagnosed, does not go to remission despite treatment (persistent), or has come back (recurrent). Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Galunisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel, carboplatin, and galunisertib may work better in treating patients with uterine, ovarian, fallopian tube, or peritoneal carcinosarcoma.
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma